KALA BIO, Inc. (KALA)
(Delayed Data from NSDQ)
$5.40 USD
+0.10 (1.89%)
Updated Oct 4, 2024 03:02 PM ET
After-Market: $5.40 0.00 (0.00%) 7:58 PM ET
2-Buy of 5 2
F Value D Growth F Momentum F VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$5.40 USD
+0.10 (1.89%)
Updated Oct 4, 2024 03:02 PM ET
After-Market: $5.40 0.00 (0.00%) 7:58 PM ET
2-Buy of 5 2
F Value D Growth F Momentum F VGM
Zacks News
Kala Pharmaceuticals (KALA) May Report Negative Earnings: Know the Trend Ahead of Q3 Release
by Zacks Equity Research
Kala Pharma (KALA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Earnings Preview: Kala Pharmaceuticals (KALA) Q2 Earnings Expected to Decline
by Zacks Equity Research
Kala Pharma (KALA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Kala Pharmaceuticals (KALA) Reports Q1 Loss, Misses Revenue Estimates
by Zacks Equity Research
Kala Pharma (KALA) delivered earnings and revenue surprises of 3.92% and -10.28%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
Viatris (VTRS) to Report Q1 Earnings: What's in the Cards?
by Zacks Equity Research
Investors will look forward to regular top and bottom-line numbers and updates on the merger synergies when Viatris (VTRS) reports Q1 results.
Tilray (TLRY) to Report Q1 Earnings: What's in the Cards?
by Zacks Equity Research
Investors will focus on revenue growth and other pipeline updates, when Tilray (TLRY) reports first-quarter 2021 results.
Is a Beat in the Cards for Twist (TWS) This Earnings Season?
by Zacks Equity Research
Investors will focus on the top-line and bottom-line numbers when Twist (TWST) reports fiscal second-quarter 2021 results.
Kala Pharmaceuticals (KALA) Reports Q4 Loss, Lags Revenue Estimates
by Zacks Equity Research
Kala Pharma (KALA) delivered earnings and revenue surprises of -19.57% and -6.44%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?
Kala Pharmaceuticals (KALA) Expected to Beat Earnings Estimates: Should You Buy?
by Zacks Equity Research
Kala Pharma (KALA) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Kala Pharmaceuticals (KALA) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
Kala Pharma (KALA) delivered earnings and revenue surprises of -13.64% and 9.74%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?
Kala Pharmaceuticals (KALA) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
by Zacks Equity Research
Kala Pharma (KALA) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Biotech Stock Roundup: GILD's Veklury Approved, NVAX Provides Vaccine Update & More
by Zacks Equity Research
Gilead (GILD) and Novavax (NVAX) continue to be in the spotlight on coronavirus-related updates.
Is the Options Market Predicting a Spike in Kala Pharmaceuticals (KALA) Stock?
by Zacks Equity Research
Investors need to pay close attention to Kala Pharmaceuticals (KALA) stock based on the movements in the options market lately.
Kala Pharmaceuticals (KALA) Looks Good: Stock Adds 6% in Session
by Zacks Equity Research
Kala Pharmaceuticals (KALA) saw a big move last session, as its shares jumped nearly 6% on the day, amid huge volumes.
Kala Pharmaceuticals (KALA) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Kala Pharma (KALA) delivered earnings and revenue surprises of 0.00% and 9.89%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?
Kala Pharmaceuticals (KALA) May Report Negative Earnings: Know the Trend Ahead of Q2 Release
by Zacks Equity Research
Kala Pharma (KALA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Is Kala Pharmaceuticals (KALA) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Is (KALA) Outperforming Other Medical Stocks This Year?
Top Ranked Momentum Stocks to Buy for May 26th
by Zacks Equity Research
Here are four stocks with buy rank and strong momentum characteristics for investors to consider today, May 26th
Has Kala Pharmaceuticals (KALA) Outpaced Other Medical Stocks This Year?
by Zacks Equity Research
Is (KALA) Outperforming Other Medical Stocks This Year?
Kala Pharmaceuticals (KALA) Reports Q1 Loss, Misses Revenue Estimates
by Zacks Equity Research
Kala Pharma (KALA) delivered earnings and revenue surprises of -5.88% and -57.02%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?
Lineage Cell (LCTX) to Post Q1 Earnings: What's in the Cards?
by Zacks Equity Research
On Lineage Cell's (LCTX) Q1 earnings call, investor focus will be on its progress with the pipeline candidate OpRegen, currently being developed for treating dry AMD, as well as other pipeline updates.
Kala Pharmaceuticals (KALA) Is Up 2.56% in One Week: What You Should Know
by Zacks Equity Research
Does Kala Pharmaceuticals (KALA) have what it takes to be a top stock pick for momentum investors? Let's find out.
Kala Pharmaceuticals' Shares March Higher, Can It Continue?
by Zacks Equity Research
As of late, it has definitely been a great time to be an investor in Kala Pharmaceuticals.
Is Kala Pharmaceuticals (KALA) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Is (KALA) Outperforming Other Medical Stocks This Year?
Here's Why Momentum Investors Will Love Kala Pharmaceuticals (KALA)
by Zacks Equity Research
Does Kala Pharmaceuticals (KALA) have what it takes to be a top stock pick for momentum investors? Let's find out.
The Zacks Analyst Blog Highlights: DHT, Summit Therapeutics, Sharps Compliance, Frontline and Kala Pharmaceuticals
by Zacks Equity Research
The Zacks Analyst Blog Highlights: DHT, Summit Therapeutics, Sharps Compliance, Frontline and Kala Pharmaceuticals